Latest news: ConcertAI’s TeraRecon Enhances its Eureka Clinical AI Platform with AI-Based Prostate Solutions from Lucida Medical
CAMBRIDGE, Mass., November 15, 2023—Concert AI’s TeraRecon, the advanced visualization and clinical AI SaaS company, announces the addition of Lucida Medical to its Eureka Clinical AI Platform ecosystem, to be deployed within the UK’s National Health Service (NHS) and European healthcare systems.
Pi™ (Prostate Intelligence™), Lucida Medical’s AI-machine learning software, is designed to help radiologists detect prostate cancer lesions from MRI, enabling faster and more accurate prostate cancer detection.
To find out more at RSNA 2023, visit Terarecon at booth #4773 or Lucida Medical at booth #4862, both in the South Hall.
Prostate cancer diagnosis just got easier with CE mark certification of Lucida Medical’s new AI software
Groundbreaking software by Lucida Medical, Pi™, demonstrates expert level of performance and exceptional promise of improving accuracy, cost, and time required in prostate cancer diagnosis.
- Prostate cancer is the most common cancer in men with 375,000 annual deaths
- Pi™ software improves the 12% “miss rate” of MRI in prostate cancer diagnosis, helping ensure patients get the treatment they need
- The software can also reduce the 55% of patients without significant cancer who are referred for costly, painful and potentially avoidable biopsy
- With an integrated, automated workflow and risk scores, the software speeds up analysis, helping hospitals tackle resourcing challenges and waiting times while giving patients the best possible outcome.
The power of AI and medical imaging to find cancer
Lucida Medical develops software based on artificial intelligence methods (machine learning and image processing) to enable radiologists to find cancer accurately, consistently and quickly using MRI.
Pi™, our first product, is a CE-marked medical device to support the analysis of MRI for prostate cancer diagnosis. Note that while we are seeking further regulatory approvals, Pi™ is not for sale or use in the USA.
We especially welcome contact from investors and healthcare professionals interested in supporting our research, joining clinical studies, or using Pi™ in the clinic in Europe or the United Kingdom.
Find out more at at upcoming conferences:
- 28 Feb-3 March 2024: ECR 2024 – exhibiting
- 26-30 Nov 2023: RSNA 2023 – exhibiting, poster, oral presentation
- 2-3 Nov 2023: BIR 2023 – two posters
Ground-breaking validation of AI for real-world prostate MRI
Dr Aarti Shah, Chief Investigator of the PAIR-1 research study, presented the latest performance results at ECR 2023 in Vienna. This work, in partnership with Hampshire Hospitals NHS Foundation Trust, shows that Pi™ can be applied to prostate MRI in routine NHS diagnostic pathways across a range of hospitals, MRI scanners and field strengths, with accuracy in line with expert prostate radiology studies.
AI in medicine - Felix Beacher from Informa interviews Lucida Medical CEO Dr Antony Rix
Can AI systems outperform radiologists in diagnosing cancer? If so, why don’t we see such systems in clinical practice? What does the future hold? And would you rather be assessed by a human physician or an algorithm?
In an episode of the brand new Medical AI Podcast, Felix Beacher, head of healthcare technology at Omdia and Informa Tech, addressed these and other issues with Antony Rix, co-founder and CEO of Lucida Medical, a company developing software to help detect prostate cancer through MRI scans.
Get in touch
To find out more, please contact us through:
We collaborate with Cambridge University, we are a partner in the ReIMAGINE prostate imaging trial, are in the process of establishing collaborative partnerships with several UK NHS Trust hospitals to help further develop and validate and test Pi, our AI system for detecting prostate cancer from MRI.